In re ViroPharma Incorporated Securities Litigation
www.viropharmasecuritieslitigation.com

WELCOME TO THE VIROPHARMA INCORPORATED SECURITIES LITIGATION WEBSITE

A proposed settlement for $8 million in cash has been reached in the In re ViroPharma Incorporated Securities Litigation. The Settlement resolves claims by Carpenters’ Local 27 Defined Benefit Trust Fund brought as a class action, alleging that ViroPharma Incorporated misled investors regarding the Company’s ability to maintain its exclusive marketing of Vancocin.

The Court in charge of the case still has to decide whether to approve the Settlement. Payments will be made if the Court approves the Settlement and after any appeals are resolved.

Please be advised that your rights will be affected if you purchased or otherwise acquired ViroPharma Securities between December 14, 2011 and April 9, 2012, inclusive.

Please be sure to read the full Notice to fully understand your rights.